Progress Toward Measles Elimination — African Region, 2013–2016

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Masresha, Balcha G. ; Dixon, Meredith G. ; Kriss, Jennifer L. ; Katsande, Reggis ; Shibeshi, Messeret E. ; Luce, Richard ; Fall, Amadou ; Dosseh, Annick R.G.A. ; Byabamazima, Charles R. ; Dabbagh, Alya J. ; Goodson, James L. ; Mihigo, Richard
• Description:
  In 2011, the 46 World Health Organization (WHO) African Region (AFR) member states established a goal of measles elimination* by 2020, by achieving 1) ≥95% coverage of their target populations with the first dose of measles-containing vaccine (MCV1) at national and district levels; 2) ≥95% coverage with measles-containing vaccine (MCV) per district during supplemental immunization activities (SIAs); and 3) confirmed measles incidence of <1 case per 1 million population in all countries (1). Two key Surveillance performance indicator targets include 1) investigating ≥2 cases of nonmeasles febrile rash illness per 100,000 population annually, and 2) obtaining a blood specimen from ≥1 suspected measles case in ≥80% of districts annually (2). This report updates the previous report (3) and describes progress toward measles elimination in AFR during 2013-2016. Estimated regional MCV1 coverage| increased from 71% in 2013 to 74% in 2015.| Seven (15%) countries achieved ≥95% MCV1 coverage in 2015.| The number of countries providing a routine second MCV dose (MCV2) increased from 11 (24%) in 2013 to 23 (49%) in 2015. Forty-one (79%) of 52 SIAs** during 2013-2016 reported ≥95% coverage. Both Surveillance targets were met in 19 (40%) countries in 2016. Confirmed measles incidence in AFR decreased from 76.3 per 1 million population to 27.9 during 2013-2016. To eliminate measles by 2020, AFR countries and partners need to 1) achieve ≥95% 2-dose MCV coverage through improved immunization services, including second dose (MCV2) introduction; 2) improve SIA quality by preparing 12-15 months in advance, and using readiness, intra-SIA, and post-SIA assessment tools; 3) fully implement elimination-standard Surveillance|; 4) conduct annual district-level risk assessments; and 5) establish national committees and a regional commission for the verification of measles elimination.
• Subjects:
  Adolescent Adult Child Child, Preschool Disease Eradication Full Report Humans Immunization Programs Immunization Schedule Incidence Infant Measles Measles Vaccine Population Surveillance Vaccination Young Adult

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 66(17):436-443.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6617a2
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  28472026
• Pubmed Central ID:
  PMC5687084
• Document Type:
  Journal Article
• Place as Subject:
  Africa
• Pages in Document:
  8 pdf pages
• Volume:
  66
• Issue:
  17
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:755e4af3578d556fe8df9e463b218802e32ade5109234ce482a22f259f59e050c2b1d8de0ca837011c4e8413eb415a503da9e1e4a090c69f168358da542ff5de
• Download URL:
  https://stacks.cdc.gov/view/cdc/54096/cdc_54096_DS1.pdf
• File Type:
  [PDF - 871.11 KB ]